Email bulletins

Archive

November 2019

• News from The Liver Meeting
• Coalition of liver associations calls for simplification of hepatitis C care
• Liver cancer survival after DAA treatment
• Organ transplants from donors with hepatitis C
• Hepatitis C incidence in Canadian men who have sex with men on PrEP
• Treatments for NASH
• Hepatitis B: antivirals reduce liver cancer risk
• Therapeutic vaccine for hepatitis B
• Is this your copy of the infohep news bulletin?

October 2019

• Tesamorelin reduces liver fat and fibrosis progression in people with HIV and NAFLD
• People who use drugs would prefer to get hepatitis C treatment at a community pharmacy
• Trivalent hepatitis B vaccine appears more effective than existing options
• Hepatitis C vaccine fails to prevent chronic infection
• Shifting demographics of the population of people with hepatitis C in the United States
• Arbutus halts early-phase hepatitis B drug trial after 2 healthy people fall ill
• Gilead faces drug pricing probe in Brazil
• News coverage of The Liver Meeting 2019
• Is this your copy of the infohep news bulletin?

September 2019

• Non-alcoholic fatty liver disease: scientists call for sugar tax
• NAFLD raises the risk of cancer in overweight people
• Fatty liver raises the risk of death in people with HIV and hepatitis C
• Does hepatitis C virus remain in the body after successful treatment?
• Curing hepatitis C may reduce inflammation in people living with HIV
• Hepatitis C undiagnosed in England
• New report calls for organisations involved with hepatitis C testing, treatment and care to improve data sharing
• Is this your copy of the infohep news bulletin?

August 2019

• FDA warns of rare cases of serious liver injury with newer hepatitis C drugs
• Voluntary licensing of hepatitis C drugs has led to more people on treatment
• Late diagnosis of hepatitis C
• Hepatitis B raises the risk of some cancers
• Young adults with vertical HIV and hepatitis C co-infection have a high hepatitis C cure rate
• 13% of HIV-positive Europeans who are cured of hepatitis C are reinfected
• Statins linked to lower risk of liver cancer in people with hepatitis B or C
• San Francisco sees new success in treating homeless people with hepatitis C
• Is this your copy of the infohep news bulletin?

July 2019

• WHO urges countries to invest in eliminating hepatitis
• 15 million affected by hepatitis in Pakistan
• World Hepatitis Day masterclasses
• Treatment in primary care improves the uptake of treatment in people who inject drugs
• UK Pharmacy Minister urged to allow pharmacist dispensing of DAAs
• Heart disease and cancers in people with HIV and hepatitis C co-infection
• Is this your copy of the infohep news bulletin?

June 2019

• African hepatitis summit
• Egypt to provide hepatitis C testing, treatment for 14 countries
• Opioid substitution prescribers and DAA treatment
• Pangenotypic treatment in France
• How much can 'Netflix'-style pricing for hepatitis C drugs save?
• Parkinson’s disease risk in people treated for hepatitis C
• Hepatitis C stigma
• Liver cancer screening
• Hepatitis C vaccine not effective
• Is this your copy of the infohep news bulletin?

May 2019

• World Health Organization calls for greater focus on people who inject drugs in HCV treatment scale-up plans
• Bulevirtide is a potential cure for hepatitis B and D
• Is opt-out testing for HCV improving testing rates in UK prisons?
• First paediatric pangenotypic treatment
• NHS England strikes world leading deal to help eliminate hepatitis C
• NHS England instructs GPs to do more hepatitis C testing after blood scandal
• Is this your copy of the infohep news bulletin?

April 2019

• News from The International Liver Congress, Vienna
• Hepatitis C elimination by 2030 in doubt as countries fail to scale up diagnosis and treatment
• 30 million screened for hepatitis C in four months in Egypt
• Same-day diagnosis and treatment initiation for viral hepatitis
• Hepatitis B cure strategy launched
• Experimental hepatitis B drug produces deep and rapid decline in HBV DNA
• Non-alcoholic fatty liver disease and NASH
• NAFLD in people living with HIV
• Simplified monitoring and highly effective treatment for hepatitis C
• Tenofovir and liver cancer in HBV
• Is this your copy of the infohep news bulletin?

March 2019

• Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up
• HCV reinfection in people who inject drugs a sign of a successful treatment programme, say researchers
• US Department of Veterans Affairs on track to cure 100,000 of hepatitis C
• Hepatitis C treatment reduces risk of diabetes
• Hepatitis C treatment safe and effective in pregnant women, pilot study shows
• Hepatitis B virus raises the risk of age-related macular degeneration
• EndHep2030 call for proposals
• World Hepatitis Alliance appoints new CEO and President
• Next month: News from The International Liver Congress
• Is this your copy of the infohep news bulletin?

February 2019

• DAA treatment reduces the risk of death and liver cancer in France
• Experimental therapy improves liver health in people with fatty liver disease
• Immunotherapy combinations show promise for liver cancer
• Generic treatment and hepatitis C elimination in Egypt
• Hepatitis C cure does not improve long-term glucose control
• Tackling HIV and hepatitis C in Europe: towards minimum standards
• Improving the uptake of hepatitis C care in people who inject drugs
• Is this your copy of the infohep news bulletin?

January 2019

• Lancet Commission recommends actions to support elimination of hepatitis C
• HCV modelling study
• HIV/HCV co-infection and end-stage liver disease
• Survival after liver cancer diagnosis is shorter in people living with HIV
• Conditional cash transfers to encourage hepatitis C diagnosis and treatment in people who inject drugs
• Barriers to HCV treatment in people who inject drugs
• TAF for hepatitis B
• AbbVie legal challenge in UK tender exercise dismissed
• Is this your copy of the infohep news bulletin?